{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:51:34Z","timestamp":1791204694383,"version":"4.2.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urogynecol J"],"DOI":"10.1007\/s00192-026-06894-z","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:59:11Z","timestamp":1791201551000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Urinary Biomarkers in Interstitial Cystitis and Bladder Pain Syndrome: A Narrative Review of Differential Diagnosis and Treatment Monitoring"],"prefix":"10.1007","author":[{"given":"Margareta","family":"Moga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5981-3802","authenticated-orcid":false,"given":"Bogdan Adrian","family":"Buhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u0103zvan-George","family":"Rahot\u0103","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana Elena","family":"Bulboac\u0103","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"6894_CR1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.urology.2003.10.034","volume":"63","author":"MB Chancellor","year":"2004","unstructured":"Chancellor MB, Yoshimura N. Treatment of interstitial cystitis. Urology. 2004;63:85\u201392. https:\/\/doi.org\/10.1016\/j.urology.2003.10.034.","journal-title":"Urology"},{"key":"6894_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9030766","volume":"9","author":"A Abdal Dayem","year":"2020","unstructured":"Abdal Dayem A, Kim K, Lee SB, Kim A, Cho S-G. Application of adult and pluripotent stem cells in interstitial cystitis\/bladder pain syndrome therapy: methods and perspectives. J Clin Med. 2020;9:766. https:\/\/doi.org\/10.3390\/jcm9030766.","journal-title":"J Clin Med"},{"key":"6894_CR3","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/j.eururo.2012.05.023","volume":"62","author":"DA Tripp","year":"2012","unstructured":"Tripp DA, Nickel JC, Wong J, Pontari M, Moldwin R, Mayer R, et al. Mapping of pain phenotypes in female patients with bladder pain syndrome\/interstitial cystitis and controls. Eur Urol. 2012;62:1188\u201394. https:\/\/doi.org\/10.1016\/j.eururo.2012.05.023.","journal-title":"Eur Urol"},{"key":"6894_CR4","doi-asserted-by":"publisher","first-page":"110","DOI":"10.62347\/BLED2401","volume":"12","author":"BMM Zwaans","year":"2024","unstructured":"Zwaans BMM, Mota S, Bartolone SN, Ward EP, Peters KM, Chancellor MB. Evaluating symptom severity and urinary cytokine levels in interstitial cystitis\/bladder pain syndrome patients, with and without Hunner\u2019s lesions. Am J Clin Exp Urol. 2024;12:110\u20138. https:\/\/doi.org\/10.62347\/BLED2401.","journal-title":"Am J Clin Exp Urol"},{"key":"6894_CR5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1749-771X.2009.01059.x","volume":"3","author":"P McDermott","year":"2009","unstructured":"McDermott P. Painful bladder syndrome\/interstitial cystitis (history, epidemiology, symptoms, diagnosis and treatments). Int J Urol Nurs. 2009;3:16\u201323. https:\/\/doi.org\/10.1111\/j.1749-771X.2009.01059.x.","journal-title":"Int J Urol Nurs"},{"key":"6894_CR6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3109\/00365599.2012.689008","volume":"46","author":"Y Logadottir","year":"2012","unstructured":"Logadottir Y, Fall M, K\u00e5bj\u00f6rn-Gustafsson C, Peeker R. Clinical characteristics differ considerably between phenotypes of bladder pain syndrome\/interstitial cystitis. Scand J Urol Nephrol. 2012;46:365\u201370. https:\/\/doi.org\/10.3109\/00365599.2012.689008.","journal-title":"Scand J Urol Nephrol"},{"key":"6894_CR7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/iju.12325","volume":"21","author":"M Fall","year":"2014","unstructured":"Fall M, Logadottir Y, Peeker R. Interstitial cystitis is bladder pain syndrome with Hunner\u2019s lesion. Int J Urol. 2014;21:79\u201382. https:\/\/doi.org\/10.1111\/iju.12325.","journal-title":"Int J Urol"},{"key":"6894_CR8","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1002\/nau.23431","volume":"37","author":"A Niimi","year":"2018","unstructured":"Niimi A, Igawa Y, Aizawa N, Honma T, Nomiya A, Akiyama Y, et al. Diagnostic value of urinary CXCL10 as a biomarker for predicting Hunner type interstitial cystitis. Neurourol Urodyn. 2018;37:1113\u20139. https:\/\/doi.org\/10.1002\/nau.23431.","journal-title":"Neurourol Urodyn"},{"key":"6894_CR9","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.eururo.2007.09.019","volume":"53","author":"JP van de Merwe","year":"2008","unstructured":"Van de Merwe JP, Nordling J, Bouchelouche P, Bouchelouche K, Cervigni M, Daha LK, et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome\/interstitial cystitis: an ESSIC proposal. Eur Urol. 2008;53:60\u20137. https:\/\/doi.org\/10.1016\/j.eururo.2007.09.019.","journal-title":"Eur Urol"},{"key":"6894_CR10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/nau.70112","volume":"45","author":"GT Werneburg","year":"2026","unstructured":"Werneburg GT, Moldwin R, Parsons CL, Priyadarshi MS, Sinha S, Clemens JQ. Interstitial cystitis\/bladder pain syndrome (IC\/BPS) diagnosis: current limitations and a pragmatic clinical diagnostic definition. Neurourol Urodyn. 2026;45:32\u20138. https:\/\/doi.org\/10.1002\/nau.70112.","journal-title":"Neurourol Urodyn"},{"issue":"Suppl 2","key":"6894_CR11","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.5213\/inj.1632712.356","volume":"20","author":"JF Jhang","year":"2016","unstructured":"Jhang JF, Kuo HC. Pathomechanism of interstitial cystitis\/bladder pain syndrome and mapping the heterogeneity of disease. Int Neurourol J. 2016;20(Suppl 2):S95\u2013104. https:\/\/doi.org\/10.5213\/inj.1632712.356.","journal-title":"Int Neurourol J"},{"key":"6894_CR12","doi-asserted-by":"publisher","first-page":"4100","DOI":"10.21037\/tau-21-657","volume":"10","author":"GT Werneburg","year":"2021","unstructured":"Werneburg GT, Keslar KS, Gotwald P, Doolittle J, Vij SC, Lee BH, et al. Neuroinflammatory gene expression analysis reveals potential novel mediators and treatment targets in interstitial cystitis with Hunner lesions. Transl Androl Urol. 2021;10:4100\u20139. https:\/\/doi.org\/10.21037\/tau-21-657.","journal-title":"Transl Androl Urol"},{"key":"6894_CR13","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/ncpuro0874","volume":"4","author":"JP van de Merwe","year":"2007","unstructured":"Van de Merwe JP. Interstitial cystitis and systemic autoimmune diseases. Nat Clin Pract Urol. 2007;4:484\u201391. https:\/\/doi.org\/10.1038\/ncpuro0874.","journal-title":"Nat Clin Pract Urol"},{"key":"6894_CR14","first-page":"243","volume":"25","author":"K Duh","year":"2018","unstructured":"Duh K, Funaro MG, DeGouveia W, Bahlani S, Pappas D, Najjar S, et al. Crosstalk between the immune system and neural pathways in interstitial cystitis\/bladder pain syndrome. Discov Med. 2018;25:243\u201350.","journal-title":"Discov Med"},{"key":"6894_CR15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/MOU.0000000000001158","volume":"34","author":"J Tornic","year":"2024","unstructured":"Tornic J, Engeler D. Latest insights into the pathophysiology of bladder pain syndrome\/interstitial cystitis. Curr Opin Urol. 2024;34:84\u20138. https:\/\/doi.org\/10.1097\/MOU.0000000000001158.","journal-title":"Curr Opin Urol"},{"key":"6894_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231912044","volume":"23","author":"YH Jiang","year":"2022","unstructured":"Jiang YH, Jhang JF, Hsu YH, Kuo HC. Usefulness of urinary biomarkers for assessing bladder condition and histopathology in patients with interstitial cystitis\/bladder pain syndrome. Int J Mol Sci. 2022;23:12044. https:\/\/doi.org\/10.3390\/ijms231912044.","journal-title":"Int J Mol Sci"},{"key":"6894_CR17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/S0090-4295(99)80333-1","volume":"49","author":"MP O\u2019Leary","year":"1997","unstructured":"O\u2019Leary MP, Sant GR, Fowler FJ, Whitmore KE, Spolarich-Kroll J. The interstitial cystitis symptom index and problem index. Urology. 1997;49:58\u201363. https:\/\/doi.org\/10.1016\/S0090-4295(99)80333-1.","journal-title":"Urology"},{"key":"6894_CR18","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1089\/jwh.2009.1702","volume":"19","author":"CW Butrick","year":"2010","unstructured":"Butrick CW, Howard FM, Sand PK. Diagnosis and treatment of interstitial cystitis\/painful bladder syndrome: a review. J Womens Health. 2010;19:1185\u201393. https:\/\/doi.org\/10.1089\/jwh.2009.1702.","journal-title":"J Womens Health"},{"key":"6894_CR19","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/nau.70144","volume":"45","author":"YC Chen","year":"2026","unstructured":"Chen YC, Tyagi P, Alperin M, Stern JNH, Lenore Ackerman A, Kuo HC. The role of biomarkers in the diagnosis and treatment of interstitial cystitis\/bladder pain syndrome: what does current evidence reveal? Neurourol Urodyn. 2026;45:60\u201370. https:\/\/doi.org\/10.1002\/nau.70144.","journal-title":"Neurourol Urodyn"},{"key":"6894_CR20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/luts.12054","volume":"7","author":"KM Peters","year":"2015","unstructured":"Peters KM, Jayabalan N, Bui D, Killinger K, Chancellor M, Tyagi P. Effect of sacral neuromodulation on outcome measures and urine chemokines in interstitial cystitis\/painful bladder syndrome patients. Low Urin Tract Symptoms. 2015;7:77\u201383. https:\/\/doi.org\/10.1111\/luts.12054.","journal-title":"Low Urin Tract Symptoms"},{"key":"6894_CR21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/nau.70099","volume":"45","author":"ME Sullivan","year":"2026","unstructured":"Sullivan ME, El Haraki A, Padoa A, Vincent K, Whitmore KE, Cervigni M. Role of gynecologic findings in interstitial cystitis\/bladder pain syndrome: a consensus. Neurourol Urodyn. 2026;45:39\u201345. https:\/\/doi.org\/10.1002\/nau.70099.","journal-title":"Neurourol Urodyn"},{"key":"6894_CR22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.urology.2024.03.043","volume":"189","author":"LE Lamb","year":"2024","unstructured":"Lamb LE, Janicki JJ, Bartolone SN, Ward EP, Abraham N, Laudano M, et al. Risk classification for interstitial cystitis\/bladder pain syndrome using machine learning based predictions. Urology. 2024;189:19\u201326. https:\/\/doi.org\/10.1016\/j.urology.2024.03.043.","journal-title":"Urology"},{"key":"6894_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10051149","volume":"10","author":"WR Yu","year":"2022","unstructured":"Yu WR, Jiang YH, Jhang JF, Kuo HC. Use of urinary cytokine and chemokine levels for identifying bladder conditions and predicting treatment outcomes in patients with interstitial cystitis\/bladder pain syndrome. Biomedicines. 2022;10:1149. https:\/\/doi.org\/10.3390\/biomedicines10051149.","journal-title":"Biomedicines"},{"key":"6894_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12010075","volume":"12","author":"HY Lin","year":"2022","unstructured":"Lin HY, Lu JH, Chuang SM, Chueh KS, Juan TJ, Liu YC, et al. Urinary biomarkers in interstitial cystitis\/bladder pain syndrome and its impact on therapeutic outcome. Diagnostics. 2022;12:75. https:\/\/doi.org\/10.3390\/diagnostics12010075.","journal-title":"Diagnostics"},{"key":"6894_CR25","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/nau.70170","volume":"45","author":"DT Wolff","year":"2026","unstructured":"Wolff DT, Langefeld CD, Call JT, Badlani G, Evans RJ, Walker SJ. Correlates of positive response to therapeutic hydrodistension in interstitial cystitis\/bladder pain syndrome. Neurourol Urodyn. 2026;45:169\u201376. https:\/\/doi.org\/10.1002\/nau.70170.","journal-title":"Neurourol Urodyn"},{"key":"6894_CR26","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/nau.70117","volume":"45","author":"H Ruetten","year":"2026","unstructured":"Ruetten H, Crawford LK, De EJB, Li W, Akiyama Y. Genomics and histopathology in interstitial cystitis\/bladder pain syndrome. Neurourol Urodyn. 2026;45:54\u20139. https:\/\/doi.org\/10.1002\/nau.70117.","journal-title":"Neurourol Urodyn"},{"key":"6894_CR27","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1002\/nau.70107","volume":"44","author":"B Hayes","year":"2025","unstructured":"Hayes B, Namugosa M, Evans RJ, Hajebrahimi S, Janssen D, King C, et al. Patient related outcomes for interstitial cystitis\/bladder pain syndrome recommendations for clinical trials and general urology practice. Neurourol Urodyn. 2025;44:1455\u201365. https:\/\/doi.org\/10.1002\/nau.70107.","journal-title":"Neurourol Urodyn"},{"key":"6894_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/bco2.70051","volume":"6","author":"T Kuret","year":"2025","unstructured":"Kuret T, Kreft ME. New insights into interstitial cystitis\/bladder pain syndrome at single-cell resolution. BJUI Compass. 2025;6:e70051. https:\/\/doi.org\/10.1002\/bco2.70051.","journal-title":"BJUI Compass"},{"key":"6894_CR29","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.euf.2025.01.008","volume":"10","author":"D Nandwana","year":"2024","unstructured":"Nandwana D, Zhang Y, Feng N. Contribution of the microbiome to interstitial cystitis\/bladder pain syndrome: a mini review. Eur Urol Focus. 2024;10:893\u20137. https:\/\/doi.org\/10.1016\/j.euf.2025.01.008.","journal-title":"Eur Urol Focus"},{"key":"6894_CR30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/nau.70098","volume":"45","author":"DT Wolff","year":"2026","unstructured":"Wolff DT, Tranchina S, Schrepf A, Doiron RC, Chai TC, Walker SJ. Interstitial cystitis\/bladder pain syndrome patient phenotyping. Neurourol Urodyn. 2026;45:19\u201325. https:\/\/doi.org\/10.1002\/nau.70098.","journal-title":"Neurourol Urodyn"},{"key":"6894_CR31","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.euros.2025.10.021","volume":"82","author":"YC Chen","year":"2025","unstructured":"Chen YC, Tian JH, Kuo HC. Integrative diagnostic model combining urinary biomarkers and clinical parameters to improve diagnostic performance in interstitial cystitis\/bladder pain syndrome. Eur Urol Open Sci. 2025;82:192\u2013200. https:\/\/doi.org\/10.1016\/j.euros.2025.10.021.","journal-title":"Eur Urol Open Sci"},{"key":"6894_CR32","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s00192-017-3547-5","volume":"29","author":"A Furuta","year":"2018","unstructured":"Furuta A, Yamamoto T, Suzuki Y, Gotoh M, Egawa S, Yoshimura N. Comparison of inflammatory urine markers in patients with interstitial cystitis and overactive bladder. Int Urogynecol J. 2018;29:961\u20136. https:\/\/doi.org\/10.1007\/s00192-017-3547-5.","journal-title":"Int Urogynecol J"},{"key":"6894_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13020369","volume":"13","author":"JH Tian","year":"2025","unstructured":"Tian JH, Tsai CY, Yu WR, Jiang YH, Jhang JF, Kuo HC. Clustering of urinary biomarkers to identify interstitial cystitis subtypes and different clinical characteristics and treatment outcomes. Biomedicines. 2025;13:369. https:\/\/doi.org\/10.3390\/biomedicines13020369.","journal-title":"Biomedicines"},{"key":"6894_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-80131-5","volume":"11","author":"YH Jiang","year":"2021","unstructured":"Jiang YH, Jhang JF, Hsu YH, Ho HC, Wu YH, Kuo HC. Urine biomarkers in ESSIC type 2 interstitial cystitis\/bladder pain syndrome and overactive bladder with developing a novel diagnostic algorithm. Sci Rep. 2021;11:914. https:\/\/doi.org\/10.1038\/s41598-020-80131-5.","journal-title":"Sci Rep"},{"key":"6894_CR35","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1007\/s11255-026-05065-9","volume":"58","author":"JH Tian","year":"2026","unstructured":"Tian JH, Yu WR, Jhang JF, Jiang YH, Kuo HC. External validation of combining clinical parameters and urinary biomarker clusters and development of a nomogram for identifying bladder-centric interstitial cystitis\/bladder pain syndrome in patients with lower urinary tract symptoms. Int Urol Nephrol. 2026;58:3069\u201378. https:\/\/doi.org\/10.1007\/s11255-026-05065-9.","journal-title":"Int Urol Nephrol"},{"key":"6894_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0185686","volume":"12","author":"LE Lamb","year":"2017","unstructured":"Lamb LE, Janicki JJ, Bartolone SN, Peters KM, Chancellor MB. Development of an interstitial cystitis risk score for bladder permeability. PLoS ONE. 2017;12:e0185686. https:\/\/doi.org\/10.1371\/journal.pone.0185686.","journal-title":"PLoS ONE"},{"key":"6894_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12051093","volume":"12","author":"YH Jiang","year":"2022","unstructured":"Jiang YH, Jhang JF, Kuo HC. Can we use urinary cytokine\/chemokine analysis in discriminating ulcer-type interstitial cystitis\/bladder pain syndrome? Diagnostics (Basel). 2022;12:1093. https:\/\/doi.org\/10.3390\/diagnostics12051093.","journal-title":"Diagnostics (Basel)"},{"key":"6894_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26083712","volume":"26","author":"YH Jiang","year":"2025","unstructured":"Jiang YH, Jhang JF, Wang JH, Wu YH, Kuo HC. Applying K-means cluster analysis to urinary biomarkers in interstitial cystitis\/bladder pain syndrome: a new perspective on disease classification. Int J Mol Sci. 2025;26:3712. https:\/\/doi.org\/10.3390\/ijms26083712.","journal-title":"Int J Mol Sci"},{"key":"6894_CR39","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.urology.2018.02.039","volume":"116","author":"PL Vera","year":"2018","unstructured":"Vera PL, Preston DM, Moldwin RM, Erickson DR, Mowlazadeh B, Ma F, et al. Elevated urine levels of macrophage migration inhibitory factor in inflammatory bladder conditions: a potential biomarker for a subgroup of interstitial cystitis\/bladder pain syndrome patients. Urology. 2018;116:55\u201362. https:\/\/doi.org\/10.1016\/j.urology.2018.02.039.","journal-title":"Urology"},{"key":"6894_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-72292-0","volume":"10","author":"YH Jiang","year":"2020","unstructured":"Jiang YH, Kuo YC, Jhang JF, Lee CL, Hsu YH, Ho HC, et al. Repeated intravesical injections of platelet-rich plasma improve symptoms and alter urinary functional proteins in patients with refractory interstitial cystitis. Sci Rep. 2020;10:15218. https:\/\/doi.org\/10.1038\/s41598-020-72292-0.","journal-title":"Sci Rep"},{"key":"6894_CR41","doi-asserted-by":"publisher","first-page":"605","DOI":"10.23736\/S2724-6051.25.06232-9","volume":"77","author":"HR Li","year":"2025","unstructured":"Li HR, Wang T, Shen SH, Peng L. The efficacy and safety of intravesical platelet-rich plasma injections into the bladder for the treatment of interstitial cystitis\/bladder pain syndrome: a systematic review and meta-analysis. Minerva Urol Nefrol. 2025;77:605\u201317. https:\/\/doi.org\/10.23736\/S2724-6051.25.06232-9.","journal-title":"Minerva Urol Nefrol"},{"key":"6894_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-87040-1","volume":"11","author":"YC Shen","year":"2021","unstructured":"Shen YC, Tyagi P, Lee WC, Chancellor M, Chuang YC. Improves symptoms and urinary biomarkers in refractory interstitial cystitis\/bladder pain syndrome patients randomized to extracorporeal shock wave therapy versus placebo. Sci Rep. 2021;11:7558. https:\/\/doi.org\/10.1038\/s41598-021-87040-1.","journal-title":"Sci Rep"},{"key":"6894_CR43","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1007\/s11255-025-04388-3","volume":"57","author":"YC Chiu","year":"2025","unstructured":"Chiu YC, Tsai PC, Jhang JF, Kuo HC. Revealing distinct treatment mechanisms and outcome correlations in patients with interstitial cystitis\/bladder pain syndrome after different bladder therapies through urinary biomarker analysis. Int Urol Nephrol. 2025;57:2073\u201380. https:\/\/doi.org\/10.1007\/s11255-025-04388-3.","journal-title":"Int Urol Nephrol"},{"key":"6894_CR44","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1007\/s11255-025-04950-z","volume":"58","author":"JF Jhang","year":"2026","unstructured":"Jhang JF, Kuo HC. Low-energy extracorporeal shock-wave therapy with or without intravesical botulinum toxin A instillations for refractory interstitial cystitis\/bladder pain syndrome: a randomized double-blind trial of clinical and biomarker outcomes. Int Urol Nephrol. 2026;58:2055\u201363. https:\/\/doi.org\/10.1007\/s11255-025-04950-z.","journal-title":"Int Urol Nephrol"},{"key":"6894_CR45","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-024-04843-3","volume":"42","author":"JF Jhang","year":"2024","unstructured":"Jhang JF, Yu WR, Huang WT, Kuo HC. Combination of urinary biomarkers and machine-learning models provided a higher predictive accuracy to predict long-term treatment outcomes of patients with interstitial cystitis\/bladder pain syndrome. World J Urol. 2024;42:173. https:\/\/doi.org\/10.1007\/s00345-024-04843-3.","journal-title":"World J Urol"},{"key":"6894_CR46","doi-asserted-by":"publisher","first-page":"181","DOI":"10.5213\/inj.2550048.024","volume":"29","author":"T Ozdemir","year":"2025","unstructured":"Ozdemir T, Aliyev B, Ergun KE, Kalemci S, Kizilay F, Azarsiz E, et al. The role of urinary secretory immunoglobulin A in the pathophysiology of interstitial cystitis. Int Neurourol J. 2025;29:181\u20137. https:\/\/doi.org\/10.5213\/inj.2550048.024.","journal-title":"Int Neurourol J"},{"key":"6894_CR47","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1007\/s00192-019-04075-9","volume":"30","author":"TF Magalhaes","year":"2019","unstructured":"Magalhaes TF, Baracat EC, Doumouchtsis SK, Haddad JM. Biomarkers in the diagnosis and symptom assessment of patients with bladder pain syndrome: a systematic review. Int Urogynecol J. 2019;30:1785\u201394. https:\/\/doi.org\/10.1007\/s00192-019-04075-9.","journal-title":"Int Urogynecol J"},{"key":"6894_CR48","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00345-012-0852-y","volume":"31","author":"AT Corcoran","year":"2013","unstructured":"Corcoran AT, Yoshimura N, Tyagi V, Jacobs B, Leng W, Tyagi P. Mapping the cytokine profile of painful bladder syndrome\/interstitial cystitis in human bladder and urine specimens. World J Urol. 2013;31:241\u20136. https:\/\/doi.org\/10.1007\/s00345-012-0852-y.","journal-title":"World J Urol"},{"key":"6894_CR49","doi-asserted-by":"publisher","first-page":"353","DOI":"10.56434\/j.arch.esp.urol.20247704.48","volume":"77","author":"L Wang","year":"2024","unstructured":"Wang L, Gao J, Zheng S, Wang Z, Zheng S, Luo Z. Potential urine and serum biomarkers in patients with bladder pain syndrome\/interstitial cystitis. Arch Esp Urol. 2024;77:353\u20138. https:\/\/doi.org\/10.56434\/j.arch.esp.urol.20247704.48.","journal-title":"Arch Esp Urol"},{"key":"6894_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12062336","volume":"12","author":"YH Jiang","year":"2023","unstructured":"Jiang YH, Jhang JF, Kuo HC. Urinary oxidative stress biomarker levels might be useful in identifying functional bladder disorders in women with frequency and urgency syndrome. J Clin Med. 2023;12:2336. https:\/\/doi.org\/10.3390\/jcm12062336.","journal-title":"J Clin Med"},{"key":"6894_CR51","doi-asserted-by":"publisher","first-page":"110","DOI":"10.4103\/tcmj.tcmj_221_23","volume":"36","author":"WR Yu","year":"2024","unstructured":"Yu WR, Jiang YH, Jhang JF, Kuo HC. Urine biomarker could be a useful tool for differential diagnosis of a lower urinary tract dysfunction. Tzu Chi Med J. 2024;36:110\u20139. https:\/\/doi.org\/10.4103\/tcmj.tcmj_221_23.","journal-title":"Tzu Chi Med J"},{"key":"6894_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11122238","volume":"11","author":"Y Akiyama","year":"2021","unstructured":"Akiyama Y. Biomarkers in interstitial cystitis\/bladder pain syndrome with and without Hunner lesion: a review and future perspectives. Diagnostics (Basel). 2021;11:2238. https:\/\/doi.org\/10.3390\/diagnostics11122238.","journal-title":"Diagnostics (Basel)"},{"key":"6894_CR53","doi-asserted-by":"publisher","first-page":"135","DOI":"10.4103\/tcmj.tcmj_92_19","volume":"31","author":"QS Ke","year":"2019","unstructured":"Ke QS, Jhang JF, Lin TY, Ho HC, Jiang YH, Hsu YH, et al. Therapeutic potential of intravesical injections of platelet-rich plasma in the treatment of lower urinary tract disorders due to regenerative deficiency. Tzu Chi Med J. 2019;31:135\u201343. https:\/\/doi.org\/10.4103\/tcmj.tcmj_92_19.","journal-title":"Tzu Chi Med J"},{"key":"6894_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25010163","volume":"25","author":"JF Jhang","year":"2024","unstructured":"Jhang JF, Jiang YH, Lin TY, Kuo HC. The Tumor Necrosis Factor-\u03b1 level in platelet-rich plasma might be associated with treatment outcome in patients with interstitial cystitis\/bladder pain syndrome or recurrent urinary tract infection. Int J Mol Sci. 2024;25:163. https:\/\/doi.org\/10.3390\/ijms25010163.","journal-title":"Int J Mol Sci"},{"key":"6894_CR55","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1002\/nau.25267","volume":"42","author":"AM Shah","year":"2023","unstructured":"Shah AM, Vodovotz Y, Yoshimura N, Chermansky CJ, Fitzgerald J, Tyagi P. Temporally complex inflammatory networks in an animal model reveal signatures for interstitial cystitis and bladder pain syndrome phenotype. Neurourol Urodyn. 2023;42:1839\u201348. https:\/\/doi.org\/10.1002\/nau.25267.","journal-title":"Neurourol Urodyn"}],"container-title":["International Urogynecology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-026-06894-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00192-026-06894-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-026-06894-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:59:12Z","timestamp":1791201552000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00192-026-06894-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":55,"alternative-id":["6894"],"URL":"https:\/\/doi.org\/10.1007\/s00192-026-06894-z","relation":{},"ISSN":["0937-3462","1433-3023"],"issn-type":[{"value":"0937-3462","type":"print"},{"value":"1433-3023","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"assertion":[{"value":"7 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Margareta Moga certifies that there were no conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (e.g., employment\/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending).","order":1,"name":"Ethics","label":"Financial Disclosures","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. No Institutional Review Board or ethics committee approval was required for this narrative review of previously published literature.","order":2,"name":"Ethics","label":"Ethical or Institutional Review Board Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":3,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}